Cysteine-mutations in von Willebrand factor associated with increased clearance

被引:76
作者
Schooten, CJ
Tjernberg, P
Westein, E
Terraube, V
Castaman, G
Van Mourik, JA
Hollestelle, MJ
Vos, HL
Bertina, RM
Van Den Berg, HM
Eikenboom, JCJ
Lenting, PJ
Denis, CV
机构
[1] Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands
[2] Leiden Univ, Med Ctr, Dept Haematol, Hemostasis & Thrombosis Res Ctr, Leiden, Netherlands
[3] INSERM, U143, F-94275 Le Kremlin Bicetre, France
[4] San Bartolo Hosp, Dept Cellular Therapies & Hematol, Vicenza, Italy
[5] Sanquin Res, CLB, Dept Plasma Prot, Amsterdam, Netherlands
[6] Univ Utrecht, Med Ctr, Von Creveld Clin, Utrecht, Netherlands
关键词
ADAMTS-13; propeptide; recombinant VWF; VWF-deficient mice;
D O I
10.1111/j.1538-7836.2005.01571.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: von Willebrand disease (VWD) is a bleeding disorder caused by the decrease of functional von Willebrand factor (VWF). Low levels of VWF can result from decreased synthesis, impaired secretion, increased clearance or combinations thereof. Several mutations lead to impaired synthesis or secretion of VWF, however, little is known about the survival of VWF in the circulation. Objectives: To evaluate the effect of several VWF mutations on VWF clearance. Patients/methods.- The effect of three cysteine-mutations (C1130F, C1149R or C2671Y) on the in vivo survival of VWF was studied in patients carrying these mutations and in a VWF-deficient mice model. Results: In patients carrying these mutations, we observed increased propeptide/mature VWF ratios and rapid disappearance of VWF from the circulation after desinopressin treatment. Detailed analysis of in vivo clearance of recombinant VWF in a VWF-deficient mice model revealed a fourfold increased clearance rate of the mutants. The mutations C1130F, C1149R and C2671Y are each associated with reduced survival of VWF in the circulation. Detailed analysis of the recombinant mutant VWF demonstrated that increased clearance was not due to increased proteolysis by ADAMTS-13. We did not identify functional or structural characteristics that the mutant proteins have in common and could be associated with the phenomenon of increased clearance. Conclusions: Cysteine-mutations in VWF may result in reduced in vivo survival. The observation that various mutations are associated with increased it? vivo clearance may have major implications for the therapeutic strategies that rely on the rise of endogenous VWF after desmopressin administration.
引用
收藏
页码:2228 / 2237
页数:10
相关论文
共 32 条
[1]   Type I von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers:: a possible general mechanism for dominant mutations of oligomeric proteins [J].
Bodó, I ;
Katsumi, A ;
Tuley, EA ;
Eikenboom, JCJ ;
Dong, ZY ;
Sadler, JE .
BLOOD, 2001, 98 (10) :2973-2979
[2]   Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13) [J].
Böhm, M ;
Vigh, T ;
Scharrer, I .
ANNALS OF HEMATOLOGY, 2002, 81 (08) :430-435
[3]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[4]   An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13 [J].
Bowen, DJ ;
Collins, PW .
BLOOD, 2004, 103 (03) :941-947
[5]   Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? [J].
Brown, SA ;
Eldridge, A ;
Collins, PW ;
Bowen, DJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) :1714-1717
[6]  
Castaman G, 2000, THROMB HAEMOSTASIS, V84, P729
[7]   Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect [J].
Castaman, G ;
Eikenboom, JCJ ;
Missiaglia, E ;
Rodeghiero, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) :876-879
[8]   A mouse model of severe von Willebrand disease:: Defects in hemostasis and thrombosis [J].
Denis, C ;
Methia, N ;
Frenette, PS ;
Rayburn, H ;
Ullman-Culleré, M ;
Hynes, RO ;
Wagner, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9524-9529
[9]   Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor [J].
Eikenboom, JCJ ;
Matsushita, T ;
Reitsma, PH ;
Tuley, EA ;
Castaman, G ;
Briet, E ;
Sadler, JE .
BLOOD, 1996, 88 (07) :2433-2441
[10]  
Eikenboom JCJ, 1998, THROMB HAEMOSTASIS, V79, P709